## CVS: CVS Health Corporation - XLV: Healthcare

### Executive Summary

No clear thesis: MRS_10 at 3.3%, does not meet entry criteria. Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($76.61)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. CVS Health offering measles vaccine to South Carolina residents amid the state's current outbreak**
- Source: Financial Times | 20251211T163217 | Bullish | Relevance: 99%
- CVS Health is offering the measles-mumps-rubella (MMR) vaccine at its CVS Pharmacy and MinuteClinic locations in South Carolina due to a current measles outbreak in the state. The vaccine is available to residents aged three and older at CVS Pharmacy, while MinuteClinic provides the second vaccination dose to children aged 4-6. This initiative aims to help protect the public from the highly contagious disease, with both walk-ins and scheduled appointments encouraged.

**2. CVS forecasts 2026 profit above estimates as turnaround plan takes effect**
- Source: CNBC | 20251209T120758 | Bullish | Relevance: 99%
- CVS Health has forecasted its 2026 profit above Wall Street estimates, signaling successful progress in its turnaround strategy that includes cost-cutting and market exits. The company also raised its 2025 profit outlook for the fourth time, with shares rising 2.4% in premarket trading. This positive outlook follows a year of significant overhaul led by CEO David Joyner, which has restored investor confidence and seen CVS shares surge 70.5% this year.

**3. CVS Health Corp Updates Financial Guidance and Strategic Initiatives**
- Source: TradingView | 20251209T114532 | Bullish | Relevance: 99%
- CVS Health Corp updated its financial guidance and strategic priorities at its 2025 Investor Day on December 9, 2025. The company raised its 2025 revenue guidance to at least $400 billion, introduced 2026 revenue guidance of at least $400 billion, and committed to mid-teens Adjusted EPS CAGR through 2028. Additionally, CVS Health launched a new consumer engagement platform to simplify care and aims to transform consumer experiences and partnerships.

**4. CVS Forecasts 2026 Revenue Short of Wall Street Estimates**
- Source: Bloomberg.com | 20251209T113000 | Neutral | Relevance: 99%
- CVS Health Corp. has provided 2026 revenue guidance of at least $400 billion, falling short of Wall Street's average estimate of $418.3 billion. The company is facing a challenging retail environment and increased government scrutiny within the healthcare sector. However, its adjusted earnings forecast of up to $7.20 per share for 2026 surpassed analyst expectations.

**5. CVS Health (NYSE: CVS) offers MMR vaccines in South Carolina amid measles outbreak**
- Source: Stock Titan | 20251211T160753 | Neutral | Relevance: 98%
-  CVS Health (NYSE: CVS) is providing measles-mumps-rubella (MMR) vaccines at over 200 CVS Pharmacy and MinuteClinic locations across South Carolina to address a current measles outbreak. This initiative allows walk-ins, with appointments encouraged, and targets patients aged 3 and older, including a recommended second dose for children aged 4-6 at MinuteClinic. The company also announced an investor day event and positive financial guidance for 2025, highlighting its strategic initiatives alongside public health efforts.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 8, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Truist Securiti | $98 | $95 | +3% |
| 2025-12-10 | Piper Sandler | $101 | $99 | +2% |
| 2025-12-10 | UBS | $97 | $96 | +1% |
| 2025-12-10 | Barclays | $93 | $87 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Truist Securiti | main | Buy |
| 2025-12-10 | Piper Sandler | reit | Overweight |
| 2025-12-10 | UBS | main | Buy |
| 2025-12-10 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 11 ($1.40M) |
| Sells | 4 ($2.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 9.4% (-2.3%)
- Vanguard Group Inc: 9.4% (-1.3%)
- Dodge & Cox Inc.: 5.8% (-0.1%)
- JPMORGAN CHASE & CO: 5.6% (+162.5%)
- Capital World Invest: 5.4% (+2.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 8 raises (avg +6%) could attract flows.
- Momentum building: MRS_10 improving +7.8% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.67 indicates undervaluation relative to growth. Analyst sentiment positive (8 raises, avg +6%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $102.6B |
| Beta | 0.48 |
| 52W Range | $43.56 - $85.15 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.67 |
| Forward P/E | 11.3 |
| Current P/E | 12.1 |
| YoY Growth | 7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -4.5% to 3.3% (+7.8% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 74th percentile. MRS_5 at 3.6% confirms short-term momentum alignment. Outperforming sector by 5.6pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 59.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.32% (CS: 74) | Strong |
| RSI_14 | 58.6 | Neutral |
| MACD Histogram | 0.23 | Bullish |
| vs SMA20 | 1.037x | Above |
| vs SMA50 | 1.025x | Above |
| vs SMA200 | 1.155x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $80.83
- **Stop Loss:** $76.61 (5.2% risk)
- **Target:** $85.05 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 327
- **Position Value:** $26,431.41
- **Portfolio %:** 26.43%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-11 (Est: $0.96)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.36 | $1.60 | +17.9% |
| 2025Q2 | $1.46 | $1.81 | +23.8% |
| 2025Q1 | $1.67 | $2.25 | +34.5% |
| 2024Q4 | $0.92 | $1.19 | +29.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*